Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-25-001912
Filing Date
2025-07-01
Accepted
2025-07-01 19:40:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 17495
2 ex991to13d12766tcrt_070125.htm EX-99.1 3975
  Complete submission text file 0000921895-25-001912.txt   23094
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-79364 | Film No.: 251097994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 141 MECOX ROAD WATER MILL NY 11976
Business Address
Postma Robert W (Filed by) CIK: 0001827847 (see all company filings)

Type: SCHEDULE 13D